Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 12/20 | 0.53 |
| ▸ | MAOA | P21397 | 7/20 | 0.53 |
| ▸ | ACACB | O00763 | 1/20 | 0.50 |
| ▸ | TOP1 | P11387 | 1/20 | 0.49 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.48 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.48 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.47 |
| ▸ | GRM5 | P41594 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.45 |
| ▸ | RELA | Q04206 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29637117 | 1.00 | NOTUM (0.54) | NOTUMMAOBMAOAACACBTOP1 | |
| SCHEMBL14031614 | 0.78 | CYP2D6 (0.47) | MAOBMAOAACACBSRD5A1GRM5 | |
| SCHEMBL4798515 | 0.74 | HSD17B3 (0.48) | MAOBMAOAACACBGRM5ALDH1A1 | |
| SCHEMBL4798520 | 0.74 | HSD17B3 (0.48) | MAOBMAOAACACBGRM5ALDH1A1 | |
| SCHEMBL2524800 | 0.72 | MAOB (0.84) | MAOBMAOATOP1GRM5NPC1 | |
| SCHEMBL30353268 | 0.72 | MAOB (0.84) | MAOBMAOATOP1GRM5NPC1 | |
| SCHEMBL17583933 | 0.71 | MAOA (0.52) | MAOBMAOAACACBTOP1S1PR1 | |
| SCHEMBL30003296 | 0.71 | NOTUM (1.00) | NOTUMALDH1A1RAB9A | |
| SCHEMBL29289495 | 0.71 | PARK7 (0.54) | MAOBMAOATOP1SRD5A1GRM5 | |
| SCHEMBL31419920 | 0.71 | PARK7 (0.54) | MAOBMAOATOP1SRD5A1GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12502440-B2 | Cross-linking compounds and methods of use thereof | NORTH CAROLINA STATE UNIVERSITY (US) | 2025-12-23 | — | — | US | disclosed |
| US-20230001024-A1 | CROSS-LINKING COMPOUNDS AND METHODS OF USE THEREOF | NORTH CAROLINA STATE UNIVERSITY | 2023-01-05 | — | — | US | disclosed |
| CN-114502171-A | Crosslinking compounds and methods of use thereof | 北卡罗莱纳州立大学 | 2022-05-13 | — | — | CN | disclosed |
| WO-2021016548-A1 | POLYIODIDE BINDING COMPOUNDS AND METHODS OF USE THEREOF | NORTH CAROLINA STATE UNIVERSITY (US) | 2021-01-28 | — | — | WO | disclosed |
| WO-2021016537-A1 | CROSS-LINKING COMPOUNDS AND METHODS OF USE THEREOF | NORTH CAROLINA STATE UNIVERSITY (US) | 2021-01-28 | — | — | WO | disclosed |
| EP-1809332-B1 | COMPOSITIONS FOR MULTI-STEP DELIVERY OF HOT-SPOTS RADIATION TO CANCER CELLS | ONCOLOGIC INC (US) | 2011-12-14 | — | — | EP | disclosed |
| US-20110142756-A1 | Method And Composition For The Treatment Of Cancer By The Enzymatic Conversion Of Soluble Radioactive Toxic Precipitates In The Cancer | Rose, David S. (US) | 2011-06-16 | — | — | US | disclosed |
| US-7807136-B2 | Method and composition for the treatment of cancer by the enzymatic conversion of soluble radioactive toxic precipitates in the cancer | Rose, David S. (US) | 2010-10-05 | — | — | US | disclosed |
| US-20100062006-A9 | Method and composition for the treatment of cancer by the enzymatic conversion of soluble radioactive toxic precipitates in the cancer | MAYERS GEORGE L | 2010-03-11 | — | — | US | disclosed |
| US-7615221-B2 | Compositions and methods for treating cancer | ONCOLOGIC, INC. (US) | 2009-11-10 | — | — | US | disclosed |
| EP-1809332-A2 | COMPOSITIONS FOR MULTI-STEP DELIVERY OF HOT-SPOTS RADIATION TO CANCER CELLS | Oncologic, Inc. (US) | 2007-07-25 | — | — | EP | disclosed |
| WO-2006010165-A2 | COMPOSITIONS FOR MULTI-STEP DELIVERY OF HOT-SPOTS RADIATION TO CANCER CELLS | ONCOLOGIC, INC. (US) | 2006-01-26 | — | — | WO | disclosed |
| US-20060018908-A1 | Compositions and methods for treating cancer | ROSE, DAVID STUART | 2006-01-26 | — | — | US | disclosed |
| US-20050058652-A1 | Method and composition for the treatment of cancer by the enzymatic conversion of soluble radioactive toxic precipitates in the cancer | ROSE, DAVID STUART | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230001024-A1 | CROSS-LINKING COMPOUNDS AND METHODS OF USE THEREOF | AOX1, MTCL3, COL1A1 | NOTUM 1946/4885MAOB 163/4885MAOA 353/4885 |
| US-12502440-B2 | Cross-linking compounds and methods of use thereof | AOX1, MTCL3, COL1A1 | NOTUM 1946/4885MAOB 163/4885MAOA 353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.